1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
DAE HWA PHARM Co., Ltd.

DAE HWA PHARM Co., Ltd.

KKRX:067080
10,040.00
KRW
-270.00
(-2.62%)
133.93EPS
137.15P/E
253.67BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,257.21
7,934.66
7,859
8,050.2
6,914.16
6,229.06
6,523.56
6,317.46
6,710.2
7,567.15
8,012.15
8,434.59
8,132.79
8,134.53
Basic EPS, GAAP
95
-6
221
211
716
376
600
-116
127
64
-65
30
94
103.32
Free Cash Flow per Basic Share
616.2
94.44
-123.79
-925.37
27.56
124.49
-860.54
-446.62
-229.66
-1,362.07
-632.1
-50.51
39.79
-176.28
Dividend per Share
99.34
103.71
99.78
99.9
99.91
150.02
150.99
148.64
150.22
150.73
148.92
148.33
149.37
49.67
Book Value per Share
3,426.58
3,284.8
3,457.82
3,746.41
4,340.27
4,347.4
4,622.72
4,692.74
4,548.48
4,452.48
4,180.7
4,110.33
4,137.76
4,469.31
Tangible Book Value per Share
3,127.31
2,892.46
3,021.32
3,291.5
3,543.62
3,366.98
3,608.25
3,439.93
3,151.65
2,873.1
2,552.81
2,436.3
2,445.09
2,779.36
Basic Weighted Avg Shares
18
17
18
18
18
18
18
17
17
17
18
18
18
18
Sales/Revenue/Turnover
127,998
134,931
139,080
142,288
122,200
110,143
114,610
109,346
117,159
131,912
141,359
149,409
143,060
143,424
Operating Margin (%)
3.56
3.3
4.02
3.74
6.84
4.72
5.63
3.61
2.8
4.43
1.39
4.49
2.21
1.73
Depreciation Expense
3,366
3,343
3,569
3,877
4,191
4,478
5,663
5,668
4,818
4,541
5,871
6,405
6,267
6,245
Net Income, GAAP
1,676
-102
3,911
3,729
12,654
6,648
10,541
-2,008
2,217
1,116
-1,147
531
1,654
1,822
Effective Tax Rate (%)
39.3
121.53
36.32
38.15
26.66
38.41
36.65
- -
56.63
49.67
- -
45.16
51.24
49.49
Profit Margin (%)
1.31
-0.08
2.81
2.62
10.36
6.04
9.2
-1.84
1.89
0.85
-0.81
0.36
1.16
1.27
Working Capital
15,665
8,630
7,898
-3,558
-13,120
-11,063
-20,903
-26,681
-19,196
-32,047
-62,728
-56,085
-59,125
-58,267
LT Debt
12,045
6,111
3,889
2,222
68
322
6,484
5,541
11,066
27,559
7,730
5,718
3,830
5,460
Total Equity
62,028
58,505
61,732
73,391
83,488
83,199
84,051
86,152
83,416
81,691
77,353
76,370
79,142
85,057
Return on Invested Capital (%)
2.9
-1.05
3.91
3.14
4.94
2.5
3.01
- -
0.94
1.82
- -
2.04
0.88
0.71
Return on Capital (%)
2.39
0.68
4.75
4.06
11.08
6.01
11.01
- -
2.06
1.35
- -
1.77
1.89
2.08
Return on Common Equity (%)
2.78
-0.17
6.57
5.86
17.71
8.65
13.49
-2.49
2.74
1.42
-1.52
0.73
2.26
2.43

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
94,347
92,946
95,821
LT Borrowings
5,856
3,690
5,306
LT Finance Leases
168
140
154
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
285,697
312,026
253,666

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
64,372
62,359
66,770
Cash, Cash Equivalents & STI
7,931
6,102
10,525
Accounts Receivable, Net
22,613
19,306
20,153
Inventories
32,160
35,183
34,624
Total Current Liabilities
120,473
121,484
125,037
Payables & Accruals
- -
- -
- -
ST Debt
94,347
92,946
95,821
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.76%
-1.64%
3.63%
Free Cash Flow
18.06%
24.16%
-178.22%
Net Income, GAAP
-27.14%
-79.62%
211.15%
Sales/Revenue/Turnover
0.61%
5.67%
-4.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,694
38,800
35,811
40,104
149,409
2025
36,668
35,962
36,732
33,699
143,060
2026
37,032
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-93
24
11
89.32
30
2025
-24
-38.95
-24.47
181.38
94
2026
-13.69
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
52.37
- -
148.33
2025
- -
- -
50
- -
149.37
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Eun-Seok Kim
Full Time Employees
369
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hoengseong-gun South Korea
IPO Date
Feb 14, 2003
Website
dhpharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
DAE HWA PHARM Co., Ltd. is a South Korea-based pharmaceutical company primarily engaged in the research, development, manufacture, and distribution of prescription pharmaceuticals, over-the-counter (OTC) medicines, active pharmaceutical ingredients (APIs), and advanced transdermal drug delivery formulations. Founded in 1984, incorporated in 1989, and headquartered in Hoengseong-gun, Gangwon-do, South Korea, with executive offices in Seoul and R&D operations in Pangyo, the company operates specialized manufacturing facilities that produce finished-dosage therapeutics across multiple drug delivery platforms, notably its proprietary lipid-based self-emulsifying drug delivery system (DH-LASED) and transdermal drug delivery systems (TDDS). The company organizes its business into distinct commercial segments comprising ethical pharmaceuticals (ETC), consumer healthcare products, transdermal delivery products, API synthesis, and contract development and manufacturing organization (CDMO) services. Its core product and service portfolio includes oncology therapeutics, centered on Liporaxel (oral paclitaxel solution, DHP107) for gastric and breast cancers; respiratory and mucolytic agents, including Amistein; gastrointestinal, digestive, and antacid formulations, including Magmil; cardiovascular, anti-inflammatory, and central nervous system medications; transdermal patches, plasters, and cataplasms, including the Rivamensa Patch and analgesic pain relief patches; orally disintegrating films (ODF); synthetic active pharmaceutical ingredients; peptide-based chemical entities and hyaluronic acid materials produced through its subsidiaries, such as C-Tri Pharmaceutical Co., Redox Bio Co., and DH Horim Co.; and third-party contract manufacturing solutions for global pharmaceutical clients. DAE HWA PHARM serves domestic and international healthcare institutions, hospitals, clinics, and wholesale distributors, exporting formulations across Asia, the Middle East, South America, and Africa. In recent major strategic developments, the company secured National Medical Products Administration (NMPA) approval in China for Liporaxel for the treatment of advanced, metastatic, or recurrent gastric cancer, followed by its official inclusion in China's National Reimbursement Drug List (NRDL) effective January 2026. To support its international commercialization, the company entered strategic licensing and distribution alliances with partners including Haihe Biopharma, 3SBio, and PharmaEngine for commercial expansion across mainland China, Taiwan, and Southeast Asia, while advancing regulatory submissions for expanded therapeutic indications including first-line breast cancer.